Get started

IBB

AAAPL: Updated Outlook and Best Level to BUY/HOLD 70% gains________________________________________ Apple Outlook: July 2025–Q1 2026 After peaking near $200 in late May, Apple (AAPL) remains under correction territory despite pockets of resilience, closing July around $193. The current correction is projected to persist until Q1 2026, as global macro and policy headwinds weigh on the broader tech sector. Technicals suggest AAPL could find its cycle low between Q3 and Q4 2025, potentially setting the stage for a renewed bull run into late 2026. Pullback until 170/175 USD. 📉 Catalysts Shaping Apple’s Stock Price in 2025–26 1. AI Integration and Apple Intelligence Strength: 9/10 The roll-out of on-device Apple Intelligence features—including an upgraded Siri, ChatGPT integrations, and generative AI tools—continues to build anticipation for a major iPhone upgrade supercycle. Initial adoption has been strong, but broader impact will hinge on Q4 developer and enterprise feedback. 🤖 2. Services Segment Growth Strength: 8.5/10 Apple’s Services business (App Store, iCloud, Apple Music, AI-powered subscriptions) is projected to post double-digit growth into Q4 2025, with consensus revenue estimates at $25–27B for the quarter. Analysts see upside from new AI-driven service bundles, which could add $5–8B in annualized revenue by 2026. 💡 3. Gross Margin Expansion & Cost Efficiencies Strength: 8/10 Apple’s gross margin is forecast to improve by up to 60 basis points in Q4 2025 as the product mix tilts toward higher-margin services, and as component costs ease. Operational efficiencies from supply-chain automation may further cushion profit margins amid macro uncertainty. 📊 4. iPhone 17 Product Cycle Strength: 7.5/10 The iPhone 17 lineup—rumored to include advanced polymer batteries and potential foldable form factors—is expected to launch Q4 2025, giving Apple a competitive hardware edge versus Android rivals. Early channel checks point to pent-up demand, though upgrade rates may lag previous cycles due to consumer caution. 📱 5. Vision Pro & Hardware Diversification Strength: 7/10 Next-gen Vision Pro headsets and new AR/VR devices, boosted by Apple Intelligence, are expected to drive incremental growth in Q4 2025. However, high price points and limited mainstream adoption keep near-term impact contained. 🥽 6. Share Buybacks & Dividend Policy Strength: 7/10 Apple’s $110B share buyback authorization and steady dividend growth provide valuation support, but recent market volatility has prompted a more cautious pace of repurchases. Yield-seeking investors are watching closely for any pivot in capital return policy if macro pressures persist. 💵 7. Supply Chain & Trade Policy Risks Strength: 6.5/10 Escalating U.S.–China trade tensions—including the risk of expanded tariffs or tech export bans—remain a top concern. Apple is accelerating its assembly shift toward India and Vietnam to diversify risk, but any new policy shocks in Q4 could hit margins and unit volumes. 🌏 8. Regulatory & Antitrust Pressures Strength: 6/10 The EU’s Digital Markets Act and potential U.S. antitrust probes could force Apple to further open up its iOS ecosystem by year-end, potentially capping Services revenue growth and adding compliance costs. ⚖️ 9. Macro & Interest-Rate Environment Strength: 5/10 With the Fed signaling “higher for longer” rates through mid-2026, tech sector valuations remain under pressure. Analysts see this limiting multiple expansion even if EPS growth resumes in late 2025. 📈 10. Smartphone Market Competition Strength: 5/10 Aggressive pricing and innovation from Samsung and Chinese OEMs are intensifying competitive pressures, especially in emerging markets. Apple’s share gains are likely to slow until the macro environment improves and new hardware cycles fully materialize. 🥊 ________________________________________ Analyst Projections for Q4 2025: • Consensus Revenue: $108–112B (up ~4% YoY) • EPS Estimate: $2.30–$2.42 • Gross Margin: 45–46% • iPhone Unit Growth: 2–3% • Services Revenue: $25–27B Morgan Stanley and JP Morgan maintain “Overweight” ratings, but expect rangebound performance until macro and trade uncertainty clears. Most price targets for Q4 2025 hover between $195–$215, with upside potential post-correction into 2026. 📊 ________________________________________ Analyst / Firm Date Rating Price Target (USD) Barclays 06/24/2025 – 173 () Jefferies (E. Lee) 07/01/2025 Hold (Upgraded) 188.32 UBS (D. Vogt) 07/03/2025 – 210.00 J.P. Morgan (S. Chatterjee) 06/26/2025 Overweight 230.00 Morgan Stanley (E. Woodring) 03/12/2025 Overweight 252.00 Evercore ISI 01/31/2025 – 260.00 Redburn Partners 01/31/2025 – 230.00 D.A. Davidson (G. Luria) 05/02/2025 – 250.00 TradingView Consensus (avg) – Consensus 228.98 TipRanks Consensus (avg over 3mo) – Consensus 226.36
NASDAQ:AAPLLong
by ProjectSyndicate
56
10 Small-Cap Biotechs with Key Catalysts for 2025 July List________________________________________ 🔬 10 Small-Cap Biotechs with Key Catalysts for 2025 July List ________________________________________ 1. Allogene Therapeutics (NASDAQ: ALLO) • Catalyst: Phase 2 data for ALLO-501A (anti-CD19 CAR-T for large B-cell lymphoma) expected in H2 2025; potential pivotal data could lead to regulatory submission. • Highlights: “Off-the-shelf” allogeneic CAR-T approach could transform cell therapy; watch for manufacturing/scalability updates. ________________________________________ 2. Lixte Biotechnology (NASDAQ: LIXT) • Catalyst: Phase 2 combo trial of LB-100 (PP2A inhibitor) + immunotherapy in solid tumors, with key data expected in late 2025. • Highlights: If efficacy signals emerge, could prompt partnerships or additional trials. ________________________________________ 3. Iovance Biotherapeutics (NASDAQ: IOVA) • Catalyst: Commercial launch and sales uptake for AMTAGVI (lifileucel, first FDA-approved TIL therapy in advanced melanoma); upcoming label expansion studies in lung and cervical cancer. • Highlights: Investor focus on launch ramp, real-world data, and new trial initiations in 2025. ________________________________________ 4. RenBio (NASDAQ: RENB) • Catalyst: Phase 1/2 data for RB-100 (bispecific antibody platform in solid tumors) expected mid-to-late 2025. • Highlights: Pipeline progress and partnership announcements possible. ________________________________________ 5. IGM Biosciences (NASDAQ: IGMS) • Catalyst: Phase 2 data for IGM-2323 (CD20 x CD3 bispecific in non-Hodgkin lymphoma) expected early 2025; ongoing updates from IgM antibody platform. • Highlights: Investor interest in clinical safety, efficacy, and potential for big pharma tie-ups. ________________________________________ 6. Zura Bio (NASDAQ: ZURA) • Catalyst: Phase 2b/3 trial start and topline data for tibulizumab (IL-7Ra mAb for autoimmune diseases) expected late 2025. • Highlights: Focus on rare and orphan autoimmune indications. ________________________________________ 7. INmune Bio (NASDAQ: INMB) • Catalyst: Phase 2 Alzheimer’s data (XPro1595, targeting neuroinflammation) and oncology pipeline updates expected H1 2025. • Highlights: Any signal in Alzheimer’s is high-impact; monitoring for FDA guidance. ________________________________________ 8. Veru Inc (NASDAQ: VERU) • Catalyst: Phase 3 trial results for enobosarm (oral SARM) in advanced breast cancer expected 2025; also, COVID/sepsis drug updates. • Highlights: Regulatory clarity and partnership/M&A rumors are potential drivers. ________________________________________ 9. Century Therapeutics (NASDAQ: IPSC) • Catalyst: First-in-human data for iPSC-derived NK and CAR-T cell therapies, with updates expected at major meetings in 2025. • Highlights: Platform validation and early efficacy/safety signals. ________________________________________ 10. ProKidney (NASDAQ: PROK) • Catalyst: Phase 3 pivotal data for REACT (cell therapy for chronic kidney disease/diabetes) due late 2025. • Highlights: If positive, could become the first autologous cell therapy for kidney disease. ________________________________________ 🔎 How to Monitor These Catalysts • FDA submissions/meetings (ALLO, PROK, VERU) • Clinical trial readouts (LIXT, RENB, IGMS, ZURA, INMB, IPSC) • Commercial/launch data (IOVA) • Partnership/M&A activity (IGMS, VERU, RENB) ________________________________________ 📊 Summary Table Ticker Company Upcoming Catalyst/Event Timeframe ALLO Allogene Therapeutics Phase 2 LBCL CAR-T pivotal data H2 2025 LIXT Lixte Biotechnology LB-100 + immunotherapy Phase 2 data Late 2025 IOVA Iovance Biotherapeutics AMTAGVI launch data; label expansions Throughout 2025 RENB RenBio Bispecifics Phase 1/2 data Mid-to-late 2025 IGMS IGM Biosciences IGM-2323 Phase 2 data (lymphoma) Early 2025 ZURA Zura Bio Tibulizumab Phase 2b/3 topline data Late 2025 INMB INmune Bio Alzheimer’s/oncology trial updates H1 2025 VERU Veru Inc Enobosarm Phase 3 (breast cancer) 2025 IPSC Century Therapeutics First-in-human iPSC cell therapy data 2025 PROK ProKidney REACT Phase 3 (CKD) pivotal readout Late 2025 ________________________________________ ⚠️ Word of Caution Small-cap biotech stocks can be extremely volatile, especially around catalyst events (trial data, FDA decisions). Sharp price swings—both up and down—are common. Always conduct your own research and be aware of the risks.
NASDAQ:IBBLong
by ProjectSyndicate
30
Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025Here are 10 small cap biotech stocks with notable upcoming catalysts in 2025—ranging from trial readouts and FDA decisions to pivotal data and corporate milestones: ________________________________________ 🔬 Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025 1. Crinetics Pharmaceuticals (NASDAQ: CRNX) • Catalyst: FDA PDUFA deadline for paltusotine (oral acromegaly treatment) expected by September 25, 2025. • Focused on endocrine diseases and advancing pipeline beyond acromegaly (en.wikipedia.org). Stock market information for Crinetics Pharmaceuticals Inc (CRNX) • Crinetics Pharmaceuticals Inc is a equity in the USA market. • The price is 32.33 USD currently with a change of -0.73 USD (-0.02%) from previous close. • The latest open price was 33.1 USD and the intraday volume is 420639. • The intraday high is 33.34 USD and the intraday low is 32.32 USD. • The latest trade time is Wednesday, June 11, 23:45:00 +0300. ________________________________________ 2. Viking Therapeutics • Catalyst: Late-stage trial start for injectable weight-loss drug (GLP 1/GIP); mid-stage data readout for oral candidate due in 2025 (barrons.com). • Strong analyst sentiment: Jefferies forecasts ~223% upside ________________________________________ 3. Insmed (NASDAQ: INSM) • Catalyst: Phase III/inhalable powder treprostinil palmitil for pulmonary arterial hypertension; recent results exceeded expectations; full Phase III data due in 2025 ________________________________________ 4. Kymera Therapeutics • Catalyst: Phase I for KT 621 (oral STAT6 degrader for dermatitis/asthma); next-stage readouts expected late 2025–early 2026 • Shares rose ~50% on initial results; further trials underway ________________________________________ 5. Arcutis Biotherapeutics (NASDAQ: ARQT) • Catalyst: Technical breakout potential near $17.75; continued quarterly readouts with rising sales (33% last quarter) • Upcoming investor calls/publication strategies may accelerate momentum. ________________________________________ 6. Rhythm Pharmaceuticals (NASDAQ: RYTM) • Catalyst: With FDA-approved Imcivree for genetic obesity, further label expansion or mid-to-late-stage trial results anticipated in 2025 • Institutional buying trends and revenue growth support upcoming readouts . ________________________________________ 7. BeOne Medicines (Ticker: ONC) • Catalyst: Early human data in solid tumor oncology; multiple upcoming trials in 2025 . • Q1 2025 marked first profit; strong institutional support ________________________________________ 8. Mesoblast Ltd & Capricor Therapeutics • Catalyst: Stem-cell therapies targeting GvHD, heart failure, Duchenne muscular dystrophy—key FDA decisions expected in H2 2025 • Maxim Group flags pivotal year for approvals and stock catalysts (marketwatch.com). ________________________________________ 9. Acelyrin (NASDAQ: SLRN) • Catalyst: Phase III results for lonigutamab in thyroid eye disease; shareholder vote on Alumis merger around May 2025 • Merger closing and clinical readouts may drive volatility . ________________________________________ 10. ADC Therapeutics & Foghorn Therapeutics & Pyxis Oncology • Catalysts: Multiple preclinical/early clinical updates presented at AACR (April 2025) o ADC Therapeutics (ADCT): Readouts on 6 ADC programs (Claudin 6, NaPi2b, etc.). o Foghorn (FHTX): Preclinical updates on EP300, FHD609, FHD909. o Pyxis Oncology (PYXS): Phase I ADC and Siglec 15 antibody data. ________________________________________ 🔎 How to Monitor These Catalysts • FDA PDUFA dates (Crinetics, Mesoblast/Capricor, Viking) • Trial readouts/ASC presentations (Kymera, Insmed, ADC Therapeutics, Foghorn, Pyxis) • M&A/news events (BeOne, Acelyrin merger) ________________________________________ 📊 Summary Table Ticker Company Upcoming Catalyst Timeframe CRNX Crinetics PDUFA paltusotine NDA Sep 25, 2025 Viking Viking Therapeutics Injectable Phase III, oral Phase II data From mid-2025 INSM Insmed PAH inhalable Phase III readout Mid-to-late 2025 Kymera Kymera Therapeutics Dermatitis/asthma Phase I → Phase II Late 2025 – 2026 ARQT Arcutis Biotherapeutics Continued quarterly updates Throughout 2025 RYTM Rhythm Pharmaceuticals Label expansion/trial updates 2025 ONC BeOne Medicines Solid tumor trial data 2025 Mesoblast/Capricor Stem-cell stocks FDA decisions H2 2025 SLRN Acelyrin EMA/merger vote + Phase III readout May–Q3 2025 ADCT/FHTX/PYXS AACR presenters Academic readouts on multiple programs April 2025 ________________________________________ ⚠️ A Word of Caution Small-cap biotech involves high volatility—catalyst events often drive sharp price swings, both up and down. Thorough due diligence is essential.
NASDAQ:IBBLong
by ProjectSyndicate
31
500% gains SGMO BUY/HOLD swing trade setup🔸Hello traders, today let's review 3days price chart for SGMO. Previously One of the titans of the biotech industry then fell out of grace and dumped 95% off the highs from the prior distribution range. 🔸Currently decent recovery off the lows and also we got bullish liquidity gaps protecting downside below 1.00 USD. currently trading near 2.50 USD, however this is also heavy resistance so expecting decent pullback to pickup liquidity below before the rally resumes. 🔸Recommended strategy bulls: Bulls wait for pullback to complete near 1.00 USD. The target for the bulls is re-test of mid of the multiyear distribution range at 5-6.00 USD, so this is 500-600% gains from the recommended entry price at 1.00 USD. Keep in mind, this is a swing trade setup also a 500%+ move in biotech industry may take a while to complete, so this is a setup for patient BUY/HOLD traders. 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:SGMOLong
by ProjectSyndicate
13
EXCLUSIVE EWTX 350% BUY/HOLD techs/fundies with catalyst🔸Let's review EWTX daily price chart. Strong V-shape recovery in progress. YTD gains at 218% off the lows, which is an EXCELLENT indicator of the overall health of the stock. Trading 5% below 52 week high. 🔸Based on technicals, I envision a C*H breakout in 2025 after we hit overhead resistance we can expect a pullback in order to fill the massive liquidity gap left behind near 22 USD. currently stock is trading near 35 handle and expecting limited upside going forward into Q4 2024. Market cap is hovering near 3 Bln USD so it's not a penny stock and also market cap is not inflated. 🔸CYTK competitor stock chart on the right, similarly priced and also same line of business as EWTX. Trading at 53 USD now previously maxed out at 100 USD, current CYTK market cap is 6 Bln USD, at the peak market cap was 12 Bln USD. So potentially EWTX can do x4 from current levels in order to hit CYTK max market cap. this means x4 stock prices for EWTX from current levels, so it's 34 x 4 = 136 USD max projected stock price. 🔸My PT for EWTX in 2025 is 100 USD, based on the technicals and fundamentals. Recommended strategy bulls: wait for pullback/rejection from overhead resistance and be ready to BUY/HOLD once we do a COMPLETE gap fill of the liquidity gap near 22 USD. Target is 100 USD, 350%+ upside from entry price. Good luck traders! 🔸Below supplementary fundies info on EWTX / some info on the positive catalysts, you can dig deeper if required. 🔸Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious muscle diseases, particularly rare neuromuscular and cardiac disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company leverages its deep expertise in muscle biology to create innovative therapies aimed at unmet medical needs. 🔸Their lead product candidate, EDG-5506, is being developed to treat Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). This small molecule is designed to prevent contraction-induced muscle damage, offering potential benefits in improving muscle function for patients with ystrophinopathies. The drug is currently in Phase 2 trials, and has shown promising results in reducing muscle damage biomarkers​ ​ 🔸Another key program focuses on EDG-7500, an experimental therapy for hypertrophic cardiomyopathy (HCM). This drug is a selective sarcomere modulator designed to improve cardiac relaxation and contraction. The company initiated Phase 1 trials for EDG-7500 in 2023​. ​ 🔸Edgewise is dedicated to both advancing scientific research and engaging with patient communities, frequently collaborating with organizations such as the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy 🔸The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity. 🔸After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF. 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:EWTXLong
by ProjectSyndicate
13
IBB d2 accumulation buy/hold setup 40% gains🔸Hello guys, today let's review 2daily chart for IBB . Entering re-accumulation stage now, expecting range bound trading during autumn time season. Range defined by range highs set at 135 usd and range lows at 117 usd. 🔸Similar fractal observed in 2018/2019. Faded into range after heavy spike, re-accumulation then 50% pump later during spring 2020. 🔸Recommended strategy bulls: wait for pullback to complete and reload low near range lows close to 111/113 usd (premium prices). TP1 bulls +20% gains, TP2 bulls +40% gains. buy/hold setup for patient traders. good luck! 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBLong
by ProjectSyndicate
32
Biotech: textbook bullish continuation pattern breakoutBiotech was one of the first sectors in the market to show relative strength and catch some bids throughout the June bottoming process. IBB rallied 20% off the lows and then proceeded to consolidate sideways for 3 weeks. This Wednesday, IBB broke out of that consolidation with a gap up on heavy volume and is now finding more follow-through. Keep an eye on the old Feb/Apr highs around 135 which seems like the next target in this uptrend.
NASDAQ:IBB
by EvanMedeiros
1
IBB Biotech reversal pattern after bounce from TL; low may be inIBB bounced from the green pandemic support zone last March but have came back down to retest this zone. IBB has found support exactly on my GANN FAN line for several times before it breaks down & retested the violet downtrend line & bounced, making a reversal with a long hammer candle. IBB may close today above my GANN FAN line support confirming reversal . Closing the next few days above 124 the pre-pandemic high would give added confidence to the bottom reversal pattern. Next resistances are 127 & 136 to make a higher high. Not trading advice
NASDAQ:IBBLong
by xtremerider8
IBB D2: TOPPED OUT // correction looming // SHORT IT!(NEW)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB D4: TOPPED OUT // correction looming // SHORT IT!(NEW) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. 🔸 Summary and potential trade setup ::: IBB / Biotech sector is maxed out ::: previously a steep 100% run up ::: unsustainable ::: hype is already gone ::: 30/40% correction incoming for IBB ::: VERY limited upside from here ::: rotate out of biotech now ::: expecting correction MODE ::: alternatively you can also SHORT IT ::: SHORT IT 25% gains at least short-term ::: more coming over next few months ::: unsustainable gains, game over now ::: distribution at the TOP setup ::: spells MAJOR trouble for the BULLS ::: BEAR cubs will turn into GRIZZLY ::: expecting CORRECTION to last next 4-8 months ::: distribution at the top in progress ::: will lose up to 40% during correction ::: There is no upside in this market ::: Get out / trim exposure / or SHORT IT ::: Game over bulls and market will shift ::: into BEAR mode September/October 2020 ::: either way setting up for 40%+ correction ::: 4-8 months of correction incoming soon ::: better be prepared in advance ::: when there's GREED there's also PAIN ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9 /Combo update: N/A ::: Sentiment: BEARS ::: Sentiment outlook short-term: BEARISH RISK DISCLAIMER: Trading Crypto, Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBShort
by ProjectSyndicate
3
IBB D2: TOPPED OUT // correction looming // SHORT IT!(NEW)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB D2: TOPPED OUT // correction looming // SHORT IT!(NEW) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. 🔸 Summary and potential trade setup ::: IBB / Biotech sector is maxed out ::: previously a steep 100% run up ::: unsustainable ::: hype is already gone ::: 30/40% correction incoming for IBB ::: VERY limited upside from here ::: rotate out of biotech now ::: expecting correction MODE ::: alternatively you can also SHORT IT ::: SHORT IT 25% gains at least short-term ::: more coming over next few months ::: unsustainable gains, game over now ::: distribution at the TOP setup ::: spells MAJOR trouble for the BULLS ::: BEAR cubs will turn into GRIZZLY ::: expecting CORRECTION to last next 4-8 months ::: distribution at the top in progress ::: will lose up to 40% during correction ::: There is no upside in this market ::: Get out / trim exposure / or SHORT IT ::: Game over bulls and market will shift ::: into BEAR mode September/October 2020 ::: either way setting up for 40%+ correction ::: 4-8 months of correction incoming soon ::: better be prepared in advance ::: when there's GREED there's also PAIN ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9 /Combo update: N/A ::: Sentiment: BEARS ::: Sentiment outlook short-term: BEARISH RISK DISCLAIMER: Trading Crypto, Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:IBBShort
by ProjectSyndicate
9
Amarin Corporation: A Hidden GemGood afternoon. I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company. Summary Technical analysis On the chart, we can see the imminent completion of corrective wave 2 and the appearance of impulse wave 3. Several indicators support the uptrend, including the RSI indicator. In addition, this indicator confirms the Elliott Wave labeling. On the 1D chart, we can see an open gap in the area of $8.4-12.8 per share. The company's shares are currently in an uptrend. In addition, Amarin shares are just above the EMA 55 and EMA 89, which also confirms the uptrend. Fundamental Analysis You can read a complete fundamental analysis of the company in my analytical article in SA. Conclusion Considering the above factors, I believe that the growth of Amarin shares will continue. Disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sold securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.
NASDAQ:AMRNLong
by UnknownUnicorn28205834
2
OptiNose: Maximum OptimismGood afternoon. I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company. Summary: Technical analysis: On the chart, we can see the completion of corrective wave 2 and the emergence of impulse wave 3. According to the RSI indicator, we can see an uptrend, which confirms the labeling of the Elliott waves. On the 1D chart, we can see an open gap in the area of $6-7 per share. Currently, the company's shares are in the area of the downtrend breakout. In addition, Optinose shares have broken through EMA 55 and are just below EMA 89. Fundamental Analysis: You can read a complete fundamental analysis of the company in my analytical article in SA. Conclusion Considering the above factors, I believe that the growth of Optinose shares will continue. Disclosure: This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sold securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.
OLong
by UnknownUnicorn28205834
1
BioTech And Stay At Home Stocks Show Delta WorriesThe major indices like AMEX:SPY NASDAQ:QQQ have held up well despite talks of the delta variant though peeling back a few layers shows that there are underlying concerns. Many biotech, cloud software, and stay at home names are showing strong chart patterns that are poised to move higher. Among those names are NASDAQ:IBB NASDAQ:GILD NASDAQ:ZM CRM and NYSE:SNOW . Meanwhile other stay at home related stocks have already run wild altogether - NASDAQ:ADBE NASDAQ:DOCU AMEX:IGV NASDAQ:BNTX NASDAQ:MRNA . Investors should be cautious as these stocks may be signaling weakness in Q4 as variant fears are causing more and more corporations to require masks and as inflation gets out of hand on Main street, which could ultimately slow growth as the middle and lower class are forced to tighten belts.
NASDAQ:IBB
by aaronbasile
OPTINOSE: "Rocket launch"Greetings Summary: Fundamental Analysis: Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021 In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. This pilot study being conducted in Mexico will evaluate both the magnitude and duration of viral load reduction after a single dose of OPN-019. The Company expects top-line results from this study in second quarter 2021. The company shows stable revenue growth from year to year. Technical analysis: From May 2020 to the end of June 2020, the 5th wave movement was completed.After that, a correction began. At the moment, the company's shares are in the oversold zone according to the RSI indicator. The company has several open gaps, namely in the following areas: $ 6-7, $ 10-11 per share. At the moment, the company's shares are at a strong support level . Disclosure: I am/we are long OPTN. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.
OLong
by UnknownUnicorn11885613
1
Fluidigm is the leader in mass cytometry and microfluidicsGreetings Summary: Fundamental Analysis: Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative.Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies Fluidigm is a leader in mass cytometry. According to market research and Fluidigm, the mass cytometry market reached 2.7 billion with CAGR at 26% by 2025. The Biden administration plans to spend about $ 1.6 billion on expanding Covid-19 testing programs. Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China.According to company and third-party estimates, the addressable market for flow cytometry analysis in blood cancer in China is approximately $100 million for 2021–2023, and is growing at a double-digit rate. The company shows stable revenue growth from year to year. Technical analysis: From March 2020 to the end of September 2020, the 5th wave movement was completed.After that, a correction began, namely a double three, consisting of 2 zigzags. At the moment, the company's shares are in the oversold zone according to the RSI indicator. The company has several open gaps, namely in the following areas: $ 10-11, $ 15-19, $ 30-36 per share. At the moment, the company's shares are at a strong support level. Disclosure: I am/we are long FLDM. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.
FLong
by UnknownUnicorn11885613
1